Business News Agency January 27 News yesterday, the pharmaceutical industry index has once again received a green, according to statistics, as of Monday, the Great Wisdom Pharmaceutical Industry Index fell below 3,600 points and returned to last year's level in May. The Biggest SuperView statistics show that since November 11 last year, as of Monday, the total market value of pharmaceutical industry has lost as much as 19 billion yuan, which is equivalent to the total market value of the entire agricultural sector. On November 10 last year, the total market value of the pharmaceutical sector even exceeded the total market value of the real estate industry.
This round of declines in medical stocks began on November 11 last year. As of yesterday's close, the pharmaceutical industry has fallen by more than 19%. Pharmaceuticals such as Lianhuan Pharmaceutical and Rheinland biological products all fell more than 30%.
According to statistics, as of yesterday, the valuation level of the pharmaceutical sector has fallen from 47 times in the previous period to 40 times. This valuation has been lower than the average value of pharmaceutical stocks in the recent ten years (44 times), compared to other sectors, estimates The value is on the upper side. Although the average valuation level of the pharmaceutical sector is higher than that of banks and real estate and other cyclical industries, it is not as high as TMT, new energy, and new materials.
Some market participants believe that with the prospect of long-term and stable growth of the pharmaceutical industry, the recent adjustments just provide a good opportunity for investors to lay out the pharmaceutical industry. It is reported that the E Fund Health Care Industry Fund, which is selling well, will be closed today and will enter the establishment period.
According to Shang Securities, the average annual growth rate of the pharmaceutical market in the next five years will reach 20%. Business mergers and acquisitions are in full swing, and drug innovation is accelerating. Internationalization is a positive result, with a reasonable valuation and multiple stock opportunities. Sinopharm Securities also pointed out that in the context of the 12th five-year “structural adjustment,†the pharmaceutical industry will continue to receive policy support, and the industry will maintain a high-speed growth trend in 2011. At the same time, pharmaceutical price adjustments have brought about industry consolidation, and leading companies are expected to become bigger and stronger, and R&D and innovative companies are expected to grow.
For this year's market for pharmaceuticals, Jiang Guangze, a manager of Shanghai Congrong Investment Fund, said that the long-term bullish view on the stocks of pharmaceutical stocks should be a structural one in 2011. For pharmaceutical stocks, there should be two waves of prices, with a shock in the middle. One wave may be the annual report market, the second wave may need to wait for some negative news of the market, bringing down the industry. 2012 is the opportunity to break out.
Li Wenjian, fund manager of the E Fund Healthcare Healthcare Fund, said that the most prominent feature of the medical industry is stable growth, and the growth rate in 2011 is expected to be relatively stable. In the past few years, the growth rate of the sales revenue of the pharmaceutical industry has been measured at the lowest level of 16% and the highest rate of 28%. In the worst period of 2008, it had a 20% increase. These figures are only sales growth, profit growth will be higher, there will be a premium for stock price increases. "In 2011, all sub-sectors of medicine bred major investment themes. The entire industry can be said to be brilliant." Li Wenjian pointed out.
This round of declines in medical stocks began on November 11 last year. As of yesterday's close, the pharmaceutical industry has fallen by more than 19%. Pharmaceuticals such as Lianhuan Pharmaceutical and Rheinland biological products all fell more than 30%.
According to statistics, as of yesterday, the valuation level of the pharmaceutical sector has fallen from 47 times in the previous period to 40 times. This valuation has been lower than the average value of pharmaceutical stocks in the recent ten years (44 times), compared to other sectors, estimates The value is on the upper side. Although the average valuation level of the pharmaceutical sector is higher than that of banks and real estate and other cyclical industries, it is not as high as TMT, new energy, and new materials.
Some market participants believe that with the prospect of long-term and stable growth of the pharmaceutical industry, the recent adjustments just provide a good opportunity for investors to lay out the pharmaceutical industry. It is reported that the E Fund Health Care Industry Fund, which is selling well, will be closed today and will enter the establishment period.
According to Shang Securities, the average annual growth rate of the pharmaceutical market in the next five years will reach 20%. Business mergers and acquisitions are in full swing, and drug innovation is accelerating. Internationalization is a positive result, with a reasonable valuation and multiple stock opportunities. Sinopharm Securities also pointed out that in the context of the 12th five-year “structural adjustment,†the pharmaceutical industry will continue to receive policy support, and the industry will maintain a high-speed growth trend in 2011. At the same time, pharmaceutical price adjustments have brought about industry consolidation, and leading companies are expected to become bigger and stronger, and R&D and innovative companies are expected to grow.
For this year's market for pharmaceuticals, Jiang Guangze, a manager of Shanghai Congrong Investment Fund, said that the long-term bullish view on the stocks of pharmaceutical stocks should be a structural one in 2011. For pharmaceutical stocks, there should be two waves of prices, with a shock in the middle. One wave may be the annual report market, the second wave may need to wait for some negative news of the market, bringing down the industry. 2012 is the opportunity to break out.
Li Wenjian, fund manager of the E Fund Healthcare Healthcare Fund, said that the most prominent feature of the medical industry is stable growth, and the growth rate in 2011 is expected to be relatively stable. In the past few years, the growth rate of the sales revenue of the pharmaceutical industry has been measured at the lowest level of 16% and the highest rate of 28%. In the worst period of 2008, it had a 20% increase. These figures are only sales growth, profit growth will be higher, there will be a premium for stock price increases. "In 2011, all sub-sectors of medicine bred major investment themes. The entire industry can be said to be brilliant." Li Wenjian pointed out.
Christmas Ornaments,Clear Christmas Ornaments,Plastic Christmas Ornaments,Christmas Ball Ornament
COFCO HEBEI INTERNATIONAL TRADING CO., LTD. , https://www.cofcohb.com